VR Adviser’s 10x Genomics TXG Stock Holding History

VR Adviser’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-300,000	Closed	-$18.7M	–	23
2020 Q1	$18.7M	Buy	+300,000	New	+$23.4M	5.06%	7

Other funds holding TXG

VMV

Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMI

Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

VR Adviser's TXG Position: Q2 2020 in Review

VR Adviser sold out of 10x Genomics (TXG) in Q2 2020, closing a stake of 300,000 shares — an estimated $18.7M sold.

VR Adviser first reported a position in TXG in Q1 2020 and held it in 1 quarter. The position peaked at $18.7M in Q1 2020. 146 funds tracked by Wall St. Rank hold TXG as of Q2 2020.

VR Adviser reported no remaining 10x Genomics position as of Q2 2020 after selling out during the quarter.
VR Adviser sold 300,000 10x Genomics shares in Q2 2020, an estimated $18.7M.
VR Adviser first reported a position in 10x Genomics in Q1 2020 and held it in 1 quarter.
VR Adviser's 10x Genomics position peaked at $18.7M in Q1 2020.
146 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2020.

Based on VR Adviser's 13F filing for Q2 2020, filed 14 Aug 2020.